NDANASALSPRAY, METERED
Approved
May 2010
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
4/8 — Partial
SPRIX (ketorolac tromethamine) by Fresenius Kabi is clinical pharmacology pharmacodynamics ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (nsaid) that exhibits analgesic activity in animal models. First approved in 2010.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SPRIX is a nasal spray formulation of ketorolac tromethamine, a nonsteroidal anti-inflammatory drug (NSAID) approved in 2010. It works by inhibiting prostaglandin synthetase to provide rapid analgesic and anti-inflammatory effects, with peak analgesia occurring within 2-3 hours. The nasal route offers convenient non-oral delivery for acute pain management.
$0.002BPart D
LOE ApproachingDeclining
Approaching loss of exclusivity with minimal Medicare utilization signals team consolidation and transition focus.
Mechanism of Action
CLINICAL PHARMACOLOGY Pharmacodynamics Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug (NSAID) that exhibits analgesic activity in animal models. The mechanism of action of ketorolac, like that of other NSAIDs, is not completely understood but may be related to prostaglandin…
Worked on SPRIX at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.